… of platelet inhibition over time in patients with P2Y12 pre-treatment (green curve) and in
patients without pre-treatment (red curve). The opportunity to benefit from pre-treatment effect …

… Conclusions and Relevance In this study, pretreatment with oral P2Y12 inhibitors among
patients with NSTEACS prior to angiography, compared with treatment once coronary anatomy …

… In invasively managed acute coronary syndromes (ACS), the term “pre-treatment” usually
refers to the practice of initiating dual antiplatelet therapy, in particular an oral P2Y 12 inhibitor …

Introduction The efficacy and safety of switching P2Y 12 receptor antagonists in patients
admitted for acute coronary syndrome (ACS) remain unclear. We assessed the short-term …

Pretreatment with oral P2Y 12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor
are given to patients with suspected coronary artery disease before definition of the coronary …

… was observed at day 1 with the VerifyNow P2Y12 assay (51.5 ± 2.8 vs. 42.7 ± 3.5 PRUs; p
= 0.298), whereas ticagrelor achieved greater platelet inhibition at day 30 (48.1 ± 2.5 vs. 89.2 …

… 12 inhibitors in ACS being the best treatment for the endpoint of interest. At probability
analyses prasugrel ranked consistently highest in all 30-day and 1-year endpoints. Notably, no …

Guidelines recommend treatment with a P2Y 12 platelet adenosine diphosphate receptor
inhibitor in patients undergoing elective or urgent percutaneous coronary intervention (PCI), …

… a more contemporary approach of treatment with a novel P 2 Y 12 inhibitor. While prasugrel
… , patients treated with clopidogrel compared to those treated with novel P 2 Y 12 inhibitors …

… We included RCTs comparing different oral P2Y 12 inhibitors currently recommended for
the treatment of patients with ACS (clopidogrel, prasugrel, ticagrelor). RCTs including a guided …